Alterations of the TP53 gene in gastric and esophageal carcinogenesis

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Bellini, Marilanda Ferreira ^a   Cadamuro, Aline Cristina Targa ^b   Succi, Maysa ^b   Proença, Marcela Alcântara ^b   Silva, Ana Elizabete ^b  

^a UNIVERSIDADE DO SAGRADO CORAÇÃO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MUTANT PROTEIN; PROTEASOME; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOMA IN SITU; CHRONIC GASTRITIS; DNA DAMAGE; DNA REPAIR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOGENESIS; ESOPHAGUS DYSPLASIA; G1 PHASE CELL CYCLE CHECKPOINT; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOSITY LOSS; HUMAN; HYPOXIA; INTESTINE METAPLASIA; IONIZING RADIATION; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; OXIDATIVE STRESS; PRECANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH ULCER; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; CELL TRANSFORMATION; ESOPHAGUS TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; STOMACH TUMOR;

CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866082525     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/891961     Document Type: Review

References (141)

1. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002. Ca-A Cancer Journal for Clinicians 2005 55 2 74 108 2-s2.0-14944385553 (Pubitemid 40372904)
2. Tahara E., Genetic pathways of two types of gastric cancer. IARC Scientific Publications 2004 157 327 349 2-s2.0-1842851793
3. Bandla S., Pennathur A., Luketich J. D., Beer D. G., Lin L., Bass A. J., Godfrey T. E., Litle V. R., Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Annals of Thoracic Surgery 2012 93 4 1101 1106 2-s2.0-84859024264 10.1016/j.athoracsur.2012.01.064
4. Safatle-Ribeiro A. V., Ribeiro U. Jr., Sakai P., Clarke M. R., Fylyk S. N., Lshioka S., Gama-Rodrigue J., Finkelstein S. D., Reynolds J. C., Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus. Cancer Detection and Prevention 2000 24 1 13 23 2-s2.0-0034110364 (Pubitemid 30152736)
5. Kraichely R. E., Farrugia G., Achalasia: physiology and etiopathogenesis. Diseases of the Esophagus 2006 19 4 213 223 2-s2.0-33745863035 10.1111/j.1442-2050.2006.00569.x (Pubitemid 44027081)
6. Brücher B. L. D. M., Stein H. J., Bartels H., Feussner H., Siewert J. R., Achalasia and esophageal cancer: incidence, prevalence, and prognosis. World Journal of Surgery 2001 25 6 745 749 2-s2.0-0035015774 10.1007/s00268-001-0026-3 (Pubitemid 32531921)
7. Macedo A. M., Pena S. D. J., Genetic variability of Trypanosoma cruzi: implications for the pathogenesis of Chagas disease. Parasitology Today 1998 14 3 119 124 2-s2.0-0032032285 10.1016/S0169-4758(97)01179-4 (Pubitemid 28101510)
8. Lauren P., The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinomaan attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 1965 64 31 49 2-s2.0-12644292106
9. Correa P., A human model of gastric carcinogenesis. Cancer Research 1988 48 13 3554 3560 2-s2.0-0023690989
10. Nguyen L. T., Uchida T., Murakami K., Fujioka T., Moriyama M., Helicobacter pylori virulence and the diversity of gastric cancer in Asia. Journal of Medical Microbiology 2008 57 12 1445 1453 2-s2.0-57749200155 10.1099/jmm.0.2008/003160-0
11. Kuipers E. J., Review article: exploring the link between Helicobacter pylori and gastric cancer. Alimentary Pharmacology and Therapeutics, Supplement 1999 13 1 3 11 2-s2.0-0033040247 (Pubitemid 29142254)
12. Scholte G. H. A., Van Doorn L. J., Cats A., Bloemena E., Lindeman J., Quint W. G. V., Meuwissen S. G. M., Kuipers E. J., Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. The American Journal of Gastroenterology 2002 97 7 1687 1695 2-s2.0-0036311131 10.1016/S0002-9270(02)04131-X (Pubitemid 34761390)
13. Smith M. G., Hold G. L., Tahara E., El-Omar E. M., Cellular and molecular aspects of gastric cancer. World Journal of Gastroenterology 2006 12 18 2979 2990 2-s2.0-33744529664 (Pubitemid 43811073)
14. Ong C. A. J., Lao-Sirieix P., Fitzgerald R. C., Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World Journal of Gastroenterology 2010 16 45 5669 5681 2-s2.0-78649887198 10.3748/wjg.v16.i45.5669
15. Benchimol S., Lamb P., Crawford L. V., Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somatic Cell and Molecular Genetics 1985 11 5 505 509 2-s2.0-0022395155 (Pubitemid 16222581)
16. El-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B., Definition of a consensus binding site for p53. Nature Genetics 1992 1 1 45 49 2-s2.0-0026849821
17. Pietenpol J. A., Tokino T., Thiagalingam S., El-Deiry W. S., Kinzler K. W., Vogelstein B., Sequence-specific transcriptional activation is essential for growth suppression by p53. Proceedings of the National Academy of Sciences of the United States of America 1994 91 6 1998 2002 2-s2.0-0028209857 (Pubitemid 24092029)
18. Belyi V. A., Ak P., Markert E., Wang H., Hu W., Puzio-Kuter A., Levine A. J., The origins and evolution of the p53 family of genes. Cold Spring Harbor Perspectives in Biology 2010 2 6 a001198 2-s2.0-77955827519 10.1101/cshperspect. a001198
19. Vousden K. H., Lane D. P., p53 in health and disease. Nature Reviews Molecular Cell Biology 2007 8 4 275 283 2-s2.0-33947534030 10.1038/nrm2147 (Pubitemid 46474662)
20. Aylon Y., Oren M., New plays in the p53 theater. Current Opinion in Genetics and Development 2011 21 1 86 92 2-s2.0-79551634650 10.1016/j.gde.2010. 10.002
21. Lane D. P., p53, guardian of the genome. Nature 1992 358 6381 15 16 2-s2.0-0027109075 10.1038/358015a0
22. Suzuki K., Matsubara H., Recent advances in p53 research and cancer treatment. Journal of Biomedicine and Biotechnology 2011 2011 7 978312 2-s2.0-80052664208 10.1155/2011/978312
23. Nakagawara A., Ozaki T., P53: the attractive tumor suppressor in the cancer research field. Journal of Biomedicine and Biotechnology 2011 2011 13 2-s2.0-79251534367 10.1155/2011/603925 603925
24. Egashira A., Morita M., Yoshida R., Saeki H., Oki E., Sadanaga N., Kakeji Y., Tsujitani S. I., Maehara Y., Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients. Journal of Surgical Oncology 2011 104 2 169 175 2-s2.0-79959933173 10.1002/jso.21920
25. International Agency for Research on Cancer (IARC), Polymorphisms in TP53 gene sequence. 2012
26. Robles A. I., Harris C. C., Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harbor Perspectives in Biology 2010 2 3 a001016 2-s2.0-77955382651 10.1101/cshperspect.a001016
27. Olivier M., Eeles R., Hollstein M., Khan M. A., Harris C. C., Hainaut P., The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutation 2002 19 6 607 614 2-s2.0-0036258111 10.1002/humu.10081 (Pubitemid 34556481)
28. Petitjean A., Achatz M. I. W., Borresen-Dale A. L., Hainaut P., Olivier M., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007 26 15 2157 2165 2-s2.0-34047207337 10.1038/sj.onc.1210302 (Pubitemid 46536647)
29. Crawford L. V., Pim D. C., Lamb P., The cellular protein p53 in human tumours. Molecular Biology and Medicine 1984 2 4 261 272 2-s2.0-0021558851 (Pubitemid 16257494)
30. Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D., P53 expression in breast cancer. International Journal of Cancer 1988 41 2 178 183 2-s2.0-0023925894 (Pubitemid 18061140)
31. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B., Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992 256 5058 827 830 2-s2.0-0026510193
32. Hachiya M., Chumakov A., Miller C. W., Akashi M., Said J., Koeffler H. P., Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Research 1994 14 5 1853 1859 2-s2.0-0028604611
33. Falk G. W., Barrett's esophagus. Gastroenterology 2002 122 6 1569 1591 2-s2.0-0036091028 (Pubitemid 34533554)
34. Wild C. P., Hardie L. J., Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nature Reviews Cancer 2003 3 9 676 684 2-s2.0-0141465060 (Pubitemid 37328822)
35. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., Olaru A., Wang S., Mori Y., Deacu E., Hamilton J., Kan T., Krasna M. J., Beer D. G., Pepe M. S., Abraham J. M., Feng Z., Schmiegel W., Greenwald B. D., Meltzer S. J., Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005 24 25 4138 4148 2-s2.0-21244467485 10.1038/sj.onc.1208598 (Pubitemid 40897058)
36. Clément G., Braunschweig R., Pasquier N., Bosman F. T., Benhattar J., Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. Journal of Pathology 2006 208 1 100 107 2-s2.0-29744452213 10.1002/path.1884 (Pubitemid 43025708)
37. Schneider P. M., Casson A. G., Levin B., Garewal H. S., Hoelscher A. H., Becker K., Dittler H. J., Cleary K. R., Troster M., Siewert J. R., Roth J. A., Rice T. W., Rusch V. W., Trastek V. F., Thomas A. N., Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. The Journal of Thoracic and Cardiovascular Surgery 1996 111 2 323 333 2-s2.0-0030020089 10.1016/S0022-5223(96)70441-5 (Pubitemid 26054035)
38. Gleeson C. M., Sloan J. M., McManus D. T., Maxwell P., Arthur K., McGuigan J. A., Ritchie A. J., Russell S. E. H., Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. British Journal of Cancer 1998 77 2 277 286 2-s2.0-0031985694 (Pubitemid 28029545)
39. Reid B. J., Prevo L. J., Galipeau P. C., Sanchez C. A., Longton G., Levine D. S., Blount P. L., Rabinovitch P. S., Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. The American Journal of Gastroenterology 2001 96 10 2839 2848 2-s2.0-0034793846 10.1016/S0002-9270(01)02798-8 (Pubitemid 32959522)
40. Maley C. C., Galipeau P. C., Li X., Sanchez C. A., Paulson T. G., Reid B. J., Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Research 2004 64 10 3414 3427 2-s2.0-2442649306 10.1158/0008-5472.CAN-03-3249 (Pubitemid 38657913)
41. Madani K., Zhao R., Lim H. J., Casson A. G., Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. European Journal of Cardio-Thoracic Surgery 2010 37 6 1427 1432 2-s2.0-77952585707 10.1016/j.ejcts.2009.12.018
42. Cai Y. C., So C. K., Nie A. Y., Song Y., Yang G. Y., Wang L. D., Zhao X., Kinzy T. G., Yang C. S., Characterization of genetic alteration patterns in human esophageal squamous cell carcinoma using selected microsatellite markers spanning multiple loci. International Journal of Oncology 2007 30 5 1059 1067 2-s2.0-34447337297
43. Oki E., Zhao Y., Yoshida R., Egashira A., Ohgaki K., Morita M., Kakeji Y., Maehara Y., The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion 2009 79 1 33 39 2-s2.0-58549097657 10.1159/000167864
44. Kim S. G., Hong S. J., Kwon K. W., Jung S. W., Kim W. Y., Jung I. S., Ko B. M., Ryu C. B., Kim Y. S., Moon J. H., Kim J. O., Cho J. Y., Lee J. S., Lee M. S., Shim C. S., Kim B. S., The expression of p53, p16, cyclin D1 in esophageal squamous cell carcinoma and esophageal dysplasia. The Korean Journal of Gastroenterology 2006 48 4 269 276 2-s2.0-52149092599
45. Abedi-Ardekani B., Kamangar F., Sotoudeh M., Villar S., Islami F., Aghcheli K., Nasrollahzadeh D., Taghavi N., Dawsey S. M., Abnet C. C., Hewitt S. M., Fahimi S., Saidi F., Brennan P., Boffetta P., Malekzadeh R., Hainaut P., Extremely high TP53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. PLoS ONE 2011 6 12 e29488 2-s2.0-84455172969 10.1371/journal.pone.0029488
46. Silveira A. P. F., Manoel-Caetano F. D. S., Aoki S., Yamasaki L. H. T., Rahal P., Silva A. E., Gene mutations and polymorphisms of TP53 and FHIT in chronic esophagitis and esophageal carcinoma. Anticancer Research 2011 31 5 1685 1690 2-s2.0-79958134839
47. Saeki H., Kitao H., Yoshinaga K., Nakanoko T., Kubo N., Kakeji Y., Morita M., Maehara Y., Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clinical Cancer Research 2011 17 7 1731 1740 2-s2.0-79953294169 10.1158/1078-0432.CCR-10-1996
48. Tamura G., Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World Journal of Gastroenterology 2006 12 2 192 198 2-s2.0-33644757018 (Pubitemid 43336916)
49. Vogiatzi P., Vindigni C., Roviello F., Renieri A., Giordano A., Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. Journal of Cellular Physiology 2007 211 2 287 295 2-s2.0-34147196733 10.1002/jcp.20982 (Pubitemid 46580082)
50. Nobili S., Bruno L., Landini I., Napoli C., Bechi P., Tonelli F., Rubio C. A., Mini E., Nesi G., Genomic and genetic alterations infuence the progression of gastric cancer. World Journal of Gastroenterology 2011 17 3 290 299 2-s2.0-79955756238 10.3748/wjg.v17.i3.290
51. Iwamatsu H., Nishikura K., Watanabe H., Ajioka Y., Hashidate H., Kashimura H., Asakura H., Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer 2001 4 1 20 26 2-s2.0-0034937175 10.1007/s101200100012 (Pubitemid 32625931)
52. Liu X. P., Tsushimi K., Tsushimi M., Oga A., Kawauchi S., Furuya T., Sasaki K., Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathology International 2001 51 6 440 444 2-s2.0-0034940086 10.1046/j.1440-1827.2001.01216.x (Pubitemid 32646209)
53. Fenoglio-Preiser C. M., Wang J., Stemmermann G. N., Noffsinger A., TP53 and gastric carcinoma: a review. Human Mutation 2003 21 3 258 270 2-s2.0-0037221736 10.1002/humu.10180 (Pubitemid 36292967)
54. Nguyen T., Brunson D., Crespi C. L., Penman B. W., Wishnok J. S., Tannenbaum S. R., DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992 89 7 3030 3034 2-s2.0-0026522884
55. Chen H. C., Chen H. J., Khan M. A., Rao Z. Z., Wan X. X., Tan B., Zhang D. Z., Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China. Tumor Biology 2011 32 2 367 373 2-s2.0-79953786463 10.1007/s13277-010-0129-2
56. Zhao J., Lu Y., Shen H.-M., Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Letters 2012 314 1 8 23 2-s2.0-82355180992 10.1016/j.canlet.2011.09.040
57. Chipuk J. E., Kuwana T., Bouchier-Hayes L., Droin N. M., Newmeyer D. D., Schuler M., Green D. R., Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004 303 5660 1010 1014 2-s2.0-0842278331 10.1126/science.1092734 (Pubitemid 38209704)
58. Leu J. I. J., Dumont P., Hafey M., Murphy M. E., George D. L., Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nature Cell Biology 2004 6 5 443 450 2-s2.0-2342553892 10.1038/ncb1123 (Pubitemid 38607505)
59. Fuster J. J., Sanz-González S. M., Moll U. M., Andrés V., Classic and novel roles of p53: prospects for anticancer therapy. Trends in Molecular Medicine 2007 13 5 192 199 2-s2.0-34247597764 10.1016/j.molmed.2007. 03.002 (Pubitemid 46687126)
60. Speidel D., Transcription-independent p53 apoptosis: an alternative route to death. Trends in Cell Biology 2010 20 1 14 24 2-s2.0-72549085096 10.1016/j.tcb.2009.10.002
61. Yang Y., Deng C. S., Peng J. Z., Wong B. C. Y., Lam S. K., Xia H. H. X., Effect of Helicobacter pylori on apoptosis and apoptosis related genes in gastric cancer cells. Molecular Pathology 2003 56 1 19 24 2-s2.0-0043064185 10.1136/mp.56.1.19 (Pubitemid 36174226)
62. Naumann M., Crabtree J. E., Helicobacter pylori -induced epithelial cell signalling in gastric carcinogenesis. Trends in Microbiology 2004 12 1 29 36 2-s2.0-0346729816 10.1016/j.tim.2003.11.005 (Pubitemid 38045257)
63. Targa A. C., César A. C. G., Cury P. M., Silva A. E., Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Genetics and Molecular Research 2007 6 3 554 565 2-s2.0-36048968763 (Pubitemid 350096890)
64. Triantafyllou K., Kitsanta P., Karamanolis D. G., Kittas C., Ladas S. D., Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population. Digestive and Liver Disease 2008 40 1 39 45 2-s2.0-37149052800 10.1016/j.dld.2007.09.010 (Pubitemid 50008438)
65. Liu X., Cai H., Huang H., Long Z., Shi Y., Wang Y., The prognostic significance of apoptosis-related biological markers in chinese gastric cancer patients. PLoS ONE 2011 6 12 e29670 2-s2.0-84555191381 10.1371/journal.pone. 0029670
66. Persons D. L., Croughan W. S., Borelli K. A., Cherian R., Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genetics and Cytogenetics 1998 106 1 11 17 2-s2.0-0032191571 10.1016/S0165-4608(98) 00036-3 (Pubitemid 28483426)
67. Mueller J., Werner M., Siewert J. R., Malignant progression in Barrett's esophagus: pathology and molecular biology. Recent Results in Cancer Research 2000 155 29 41 2-s2.0-0033631528
68. Langer R., Von Rahden B. H. A., Nahrig J., Von Weyhern C., Reiter R., Feith M., Stein H. J., Siewert J. R., Höfler H., Sarbia M., Prognostic significance of expression patterns of c-erbB-2, p53, p16 INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. Journal of Clinical Pathology 2006 59 6 631 634 2-s2.0-33745110595 10.1136/jcp.2005.034298 (Pubitemid 43886048)
69. Yang Y., Fruehauf J., Xiang S., Li C. J., Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients. Cell Cycle 2006 5 13 1443 1447 2-s2.0-33746590833 (Pubitemid 44153655)
70. Cestari R., Villanacci V., Rossi E., Casa D. D., Missale G., Conio M., Grigolato P., Bassotti G., Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Letters 2007 251 2 278 287 2-s2.0-34247607162 10.1016/j.canlet.2006.11.033 (Pubitemid 46669806)
71. Bellini M. F., Leite K. R. M., Cury P. M., Silva A. E., p53, p16 and Fhit proteins expressions in chronic esophagitis and Chagas disease. Anticancer Research 2008 28 6 A 3793 3799 2-s2.0-58149174373
72. Ito S., Ohga T., Saeki H., Nakamura T., Watanabe M., Tanaka S., Kakeji Y., Maehara Y., p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. International Journal of Cancer 2005 113 1 22 28 2-s2.0-8644260860 10.1002/ijc.20500 (Pubitemid 39507306)
73. Han U., Can O. I., Han S., Kayhan B., Onal B. U., Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Diseases of the Esophagus 2007 20 5 379 385 2-s2.0-34548267676 10.1111/j.1442-2050.2007.00634.x (Pubitemid 47323676)
74. Liu G., Cescon D. W., Zhai R., Zhou W., Kulke M. H., Ma C., Xu W., Su L., Asomaning K., Heist R. S., Wain J. C., Lynch T. J., Christiani D. C., p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Diseases of the Esophagus 2010 23 1 36 39 2-s2.0-77953227791 10.1111/j.1442-2050.2009.00960.x
75. Lin D. C., Shi Z. Z., Xue L. Y., Chen W., Xu X., Han Y. L., Lv N., Wang M. R., Expression of cell cycle related proteins cyclin D1, p53 and p21 WAF1/CIP1 in esophageal squamous cell carcinoma. Yi Chuan 2010 32 5 455 460 2-s2.0-79952113977
76. Yamasaki M., Miyata H., Fujiwara Y., Takiguchi S., Nakajima K., Nishida T., Yasuda T., Matsuyama J., Mori M., Doki Y., P53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Annals of Surgical Oncology 2010 17 2 634 642 2-s2.0-77149145188 10.1245/s10434-009- 0851-4
77. César A. C. G., Borim A. A., Caetano A., Cury P. M., Silva A. E., Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genetics and Cytogenetics 2004 153 2 127 132 2-s2.0-9944235734 10.1016/j.cancergencyto.2004.01.017 (Pubitemid 39592145)
78. Gobbo César A. C., de Freitas Calmon M., Cury P. M., Caetano A., Borim A. A., Silva A. E., Genetic alterations in benign lesions: chronic gastritis and gastric ulcer. World Journal of Gastroenterology 2006 12 4 625 629 2-s2.0-33644907463 (Pubitemid 43380796)
79. Khayat A. S., Guimarães A. C., Calcagno D. Q., Seabra A. D., Lima E. M., Leal M. F., Faria M. H. G., Rabenhorst S. H. B., Assumpção P. P., Demachki S., Smith M. A. C., Burbano R. R., Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterology 2009 9, article 55 2-s2.0-68349117100 10.1186/1471-230X-9-55
80. Lu H. Z., Wu Y. P., Luo W., Han Y. L., Cai Y., Xu X., Liang J., Liu S. M., Wang M. R., Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma. Zhonghua Zhong Liu Za Zhi 2009 31 10 754 758 2-s2.0-79952118792
81. Li X., Luo F., Li Q., Xu M., Feng D., Zhang G., Wu W., Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. Oncology Reports 2011 26 6 1431 1439 2-s2.0-80053501436 10.3892/or.2011.1437
82. Jang B.-G., Kim W. H., Molecular pathology of gastric carcinoma. Pathobiology 2011 78 6 302 310 2-s2.0-82055185791 10.1159/000321703
83. Iijima K., Abe Y., Koike T., Uno K., Endo H., Hatta W., Asano N., Asanuma K., Imatani A., Shimosegawa T., Gastric cancers emerging after H. pylori eradication arise exclusively from non-acid-secreting areas. The Tohoku Journal of Experimental Medicine 2012 226 1 45 53 2-s2.0-84859929479
84. Whibley C., Pharoah P. D. P., Hollstein M., p53 polymorphisms: cancer implications. Nature Reviews Cancer 2009 9 2 95 107 2-s2.0-58849120883 10.1038/nrc2584
85. Pietsch E. C., Humbey O., Murphy M. E., Polymorphisms in the p53 pathway. Oncogene 2006 25 11 1602 1611 2-s2.0-33645117454 10.1038/sj.onc.1209367
86. Bond G. L., Levine A. J., A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007 26 9 1317 1323 2-s2.0-33847308066 10.1038/sj.onc.1210199 (Pubitemid 46328460)
87. Cescon D. W., Bradbury P. A., Asomaning K., Hopkins J., Zhai R., Zhou W., Wang Z., Kulke M., Su L., Ma C., Xu W., Marshall A. L., Heist R. S., Wain J. C., Lynch T. J., Christiani D. C., Liu G., p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clinical Cancer Research 2009 15 9 3103 3109 2-s2.0-65649089824 10.1158/1078-0432.CCR-08-3120
88. Jiang D. K., Yao L., Wang W. Z., Peng B., Ren W. H., Yang X. M., Yu L., TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World Journal of Gastroenterology 2011 17 9 1227 1233 2-s2.0-79955940986 10.3748/wjg.v17.i9.1227
89. Liu L., Wang K., Zhu Z. M., Shao J. H., Associations between p53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Archives of Medical Research 2011 42 1 60 69 2-s2.0-79952075302 10.1016/j.arcmed.2011.01.008
90. Umar M., Upadhyay R., Khurana R., Kumar S., Ghoshal U. C., Mittal B., Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population. Molecular Biology Reports 2011 39 2 1153 1162 2-s2.0-79955823119 10.1007/s11033-011-0844-9
91. Matlashewski G. J., Tuck S., Pim D., Primary structure polymorphism at amino acid residue 72 of human p53. Molecular and Cellular Biology 1987 7 2 961 963 2-s2.0-0023125537 (Pubitemid 17004567)
92. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G., Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and Cellular Biology 1999 19 2 1092 1100 2-s2.0-0032907105 (Pubitemid 29046852)
93. Francisco G., Menezes P. R., Eluf-Neto J., Chammas R., Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. International Journal of Cancer 2011 129 4 920 930 2-s2.0-79959732231 10.1002/ijc.25710
94. Dahabreh I. J., Linardou H., Bouzika P., Varvarigou V., Murray S., TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiology Biomarkers and Prevention 2010 19 7 1840 1847 2-s2.0-77954511773 10.1158/1055-9965.EPI-10-0156
95. Song H. R., Kweon S. S., Kim H. N., Piao J. M., Yun W. J., Choi J. S., Hwang J. E., Yoon J. Y., Kim H. R., Park Y. K., Kim S. H., Choi Y. D., Shin M. H., Erratum to: p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer 2011 14 3, article 248 2-s2.0-79960460334 10.1007/s10120-011-0077-6
96. Gianfagna F., De Feo E., van Duijn C. M., Ricciardi G., Boccia S., A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Current Genomics 2008 9 6 361 374 2-s2.0-54749097888 10.2174/ 138920208785699544
97. Dumont P., Leu J. I. J., Della Pietra A. C., George D. L., Murphy M., The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics 2003 33 3 357 365 2-s2.0-0037372005 10.1038/ng1093 (Pubitemid 36278852)
98. Klug S. J., Ressing M., Koenig J., Abba M. C., Agorastos T., Brenna S. M., Ciotti M., Das B. R., Del Mistro A., Dybikowska A., Giuliano A. R., Gudleviciene Z., Gyllensten U., Haws A. L., Helland A., Herrington C. S., Hildesheim A., Humbey O., Jee S. H., Kim J. W., Madeleine M. M., Menczer J., Ngan H. Y., Nishikawa A., Niwa Y., Pegoraro R., Pillai M. R., Ranzani G., Rezza G., Rosenthal A. N., Roychoudhury S., Saranath D., Schmitt V. M., Sengupta S., Settheetham-Ishida W., Shirasawa H., Snijders P. J., Stoler M. H., Suárez-Rincón A. E., Szarka K., Tachezy R., Ueda M., van der Zee A. G., von Knebel Doeberitz M., Wu M. T., Yamashita T., Zehbe I., Blettner M., TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. The Lancet Oncology 2009 10 8 772 784 2-s2.0-67651158989 10.1016/S1470-2045(09)70187-1
99. Popanda O., Edler L., Waas P., Schattenberg T., Butkiewicz D., Muley T., Dienemann H., Risch A., Bartsch H., Schmezer P., Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 2007 55 1 25 34 2-s2.0-33845933090 10.1016/j.lungcan.2006.09.006 (Pubitemid 46038874)
100. Nadji S. A., Mahmoodi M., Ziaee A. A., Naghshvar F., Torabizadeh J., Yahyapour Y., Nategh R., Mokhtari-Azad T., An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer 2007 56 2 145 151 2-s2.0-34247118262 10.1016/j.lungcan.2006.12.006 (Pubitemid 46590487)
101. Dai S., Mao C., Jiang L., Wang G., Cheng H., P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Human Genetics 2009 125 5-6 633 638 2-s2.0-67349182114 10.1007/s00439-009-0664-3
102. Lili Y., Deqiang Z., Chengwen C., Yumin M., Yi X., Yao L., Yan H., Baohui H., TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. International Journal of Cancer 2009 125 12 2903 2911 2-s2.0-72449145959 10.1002/ijc.24603
103. Damin A. P. S., Frazzon A. P. G., Damin D. C., Roehe A., Hermes V., Zettler C., Alexandre C. O. P., Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detection and Prevention 2006 30 6 523 529 2-s2.0-34548242532 10.1016/j.cdp.2006.09.007 (Pubitemid 44828290)
104. Gochhait S., Bukhari S. I., Bairwa N., Vadhera S., Darvishi K., Raish M., Gupta P., Husain S. A., Bamezai R. N., Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Research 2007 9 5, article R71 2-s2.0-40449093646
105. Baynes C., Healey C. S., Pooley K. A., Scollen S., Luben R. N., Thompson D. J., Pharoah P. D. P., Easton D. F., Ponder B. A. J., Dunning A. M., Abraham J., Ahmed S., Antoniou A., Benusiglio P., Blows F., Cebrian A., Conroy D., Curzon B., Dew G., Driver K., Field H., Harrington P., Jordan C., Lesueur F., Luccarini C., Mayes R., Munday H., Perkins B., Redman K., Shah M., Tyrer J., Smith P., West J., Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Research 2007 9 2, article R27 2-s2.0-34250188802 10.1186/bcr1669 (Pubitemid 350215160)
106. Gaudet M. M., Gammon M. D., Bensen J. T., Sagiv S. K., Shantakumar S., Teitelbaum S. L., Eng S. M., Neugut A. I., Santella R. M., Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Research and Treatment 2008 108 1 93 99 2-s2.0-43049116553 10.1007/s10549-007-9573-0 (Pubitemid 351623233)
107. Costa S., Pinto D., Pereira D., Rodrigues H., Cameselle-Teijeiro J., Medeiros R., Schmitt F., Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008 8, article 32 2-s2.0-39849089291 10.1186/1471-2407-8-32 (Pubitemid 351314953)
108. Zhang Z., Wang M., Wu D., Wang M., Tong N., Tian Y., Zhang Z., P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Research and Treatment 2010 120 2 509 517 2-s2.0-77950689604 10.1007/s10549-009-0480-4
109. Tan X. L., Nieters A., Hoffmeister M., Beckmann L., Brenner H., Chang-Claude J., Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenetics and Genomics 2007 17 8 639 645 2-s2.0-34447332275 10.1097/FPC.0b013e3280d5121c (Pubitemid 47057713)
110. Dakouras A., Nikiteas N., Papadakis E., Perakis M., Valis D., Rallis G., Tzanakis N., Peros G., Tsigkris C., Kittas C., Karakitsos P., p53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Research 2008 28 2 1039 1043 2-s2.0-42549118494 (Pubitemid 351578952)
111. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., Tan W., Liu Z., Lin D., The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Research 2005 65 20 9582 9587 2-s2.0-27144529920 10.1158/0008-5472.CAN-05-1460 (Pubitemid 41508029)
112. Yang W., Zhang Y., Tian X., Ning T., Ke Y., p53 codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. Molecular Carcinogenesis 2008 47 2 100 104 2-s2.0-38949155561 10.1002/mc.20368 (Pubitemid 351231438)
113. Shao Y., Tan W., Zhang S., P53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. Diseases of the Esophagus 2008 21 2 139 143 2-s2.0-39049155205 10.1111/j.1442-2050.2007.00746.x (Pubitemid 351247326)
114. Zhou Y., Li N., Zhuang W., Liu G. J., Wu T. X., Yao X., Du L., Wei M. L., Wu X. T., P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. International Journal of Cancer 2007 121 7 1481 1486 2-s2.0-34548285900 10.1002/ijc.22833 (Pubitemid 47328706)
115. Li T., Lu Z. M., Guo M., Wu Q. J., Chen K. N., Xing H. P., Mei Q., Ke Y., p53 Codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 2002 95 12 2571 2576 2-s2.0-0037114777 10.1002/cncr.11008 (Pubitemid 35424044)
116. Hu N., Li W. J., Su H., Wang C., Goldstein A. M., Albert P. S., Emmert-Buck M. R., Kong L. H., Roth M. J., Dawsey S. M., He L. J., Cao S. F., Ding T., Giffen C., Taylor P. R., Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China. Cancer Detection and Prevention 2003 27 2 132 138 2-s2.0-0037254305 10.1016/S0361-090X(03)00031-X (Pubitemid 36429593)
117. Cai L., Mu L. N., Lu H., Lu Q. Y., You N. C. Y., Yu S. Z., Le A. D., Zhao J., Zhou X. F., Marshall J., Heber D., Zhang Z. F., Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiology Biomarkers and Prevention 2006 15 2 294 300 2-s2.0-33644747119 10.1158/1055-9965.EPI-05-0680 (Pubitemid 43342177)
118. Hamajima N., Matsuo K., Suzuki T., Nakamura T., Matsuura A., Hatooka S., Shinoda M., Kodera Y., Yamamura Y., Hirai T., Kato T., Tajima K., No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Letters 2002 181 1 81 85 2-s2.0-18344393778 10.1016/S0304-3835(02)00041-1 (Pubitemid 34326437)
119. Vos M., Adams C. H., Victor T. C., Van Helden P. D., Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genetics and Cytogenetics 2003 140 1 23 30 2-s2.0-0037242738 10.1016/S0165-4608(02)00638- 6 (Pubitemid 36110635)
120. Piao J. M., Kim H. N., Song H. R., Kweon S. S., Choi J. S., Yoon J. Y., Chung I. J., Kim S. H., Shin M. H., p53 codon 72 polymorphism and the risk of esophageal cancer: a Korean case-control study. Diseases of the Esophagus 2011 24 8 596 600 2-s2.0-79956044135 10.1111/j.1442-2050.2011.01203.x
121. Lee J.-M., Lee Y.-C., Yang S.-Y., Shi W.-L., Lee C.-J., Luh S.-P., Chen C.-J., Hsieh C.-Y., Wu M.-T., Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. International Journal of Cancer 2000 89 5 458 464 2-s2.0-0033797888
122. Shen H., Solari A., Wang X., Zhang Z., Xu Y., Wang L., Hu X., Guo J., Wei Q., P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncology Reports 2004 11 5 1115 1120 2-s2.0-16544365295
123. Ke-Xiang Z., Yu-Min L., Xun L., Wen-Ce Z., Yong S., Tao L., Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Molecular Biology Reports 2011 39 1 723 728 2-s2.0-79955742637 10.1007/s11033-011-0791-5
124. Yang M., Guo Y., Zhang X., Miao X., Tan W., Sun T., Zhao D., Yu D., Liu J., Lin D., Interaction of p53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007 28 9 1996 2001 2-s2.0-34848875142 10.1093/carcin/bgm168 (Pubitemid 47500614)
125. Hiyama T., Tanaka S., Kitadai Y., Ito M., Sumii M., Yoshihara M., Shimamoto F., Haruma K., Chayama K., p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori -associated chronic gastritis. International Journal of Cancer 2002 100 3 304 308 2-s2.0-0037143095 10.1002/ijc.10483 (Pubitemid 34728988)
126. Yi S. Y., Lee W. J., A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World Journal of Gastroenterology 2006 12 40 6536 6539 2-s2.0-33750967914 (Pubitemid 44742591)
127. Chung W. C., Lee K. M., Lee B. I., Chun J. S., Lee S. Y., Chang U. I., Park S. H., Yang J. M., Choi K. Y., Chung I. S., p53 genetic polymorphism of gastric cancer in Korea. Korean Journal of Internal Medicine 2006 21 1 28 32 2-s2.0-33646706058 (Pubitemid 43732763)
128. Lai K. C., Chen W. C., Jeng L. B., Li S. Y., Chou M. C., Tsai F. J., Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. European Journal of Surgical Oncology 2005 31 10 1135 1140 2-s2.0-29244446243 10.1016/j.ejso.2005.07.005 (Pubitemid 41819198)
129. De Feo E., Persiani R., La Greca A., Amore R., Arzani D., Rausei S., D'Ugo D., Magistrelli P., van Duijn C. M., Ricciardi G., Boccia S., A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutation Research 2009 675 1-2 60 65 2-s2.0-64249166426 10.1016/j.mrgentox.2009.02.009
130. Sul J., Yu G. P., Lu Q. Y., Lu M. L., Setiawan V. W., Wang M. R., Guo C. H., Yu S. Z., Mu L., Cai L., Kurtz R. C., Zhang Z. F., P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Letters 2006 238 2 210 223 2-s2.0-33745109882 10.1016/j.canlet.2005.07.004 (Pubitemid 43884957)
131. Zhang Z. W., Newcomb P., Hollowood A., Feakins R., Moorghen M., Storey A., Farthing M. J. G., Alderson D., Holly J., Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clinical Cancer Research 2003 9 6 2151 2156 2-s2.0-0037501107 (Pubitemid 36687637)
132. Peixoto Guimaraes D., Hsin Lu S., Snijders P., Wilmotte R., Herrero R., Lenoir G., Montesano R., Meijer C. J. L. M., Walboomers J., Hainaut P., Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Letters 2001 162 2 231 235 2-s2.0-0035951704 10.1016/S0304-3835(00)00643-1 (Pubitemid 32056293)
133. Zhao Y., Wang F., Shan S., Zhao Y., Qiu X., Li X., Jiao F., Wang J. G., Du Y., Genetic polymorphism of p53, but not GSTP1, is association with susceptibility to esophageal cancer risk-a meta-analysis. International Journal of Medical Sciences 2010 7 5 300 308 2-s2.0-77956956029
134. Cañas M., Morán Y., Camargo M. E., Rivero M. B., Bohórquez A., Villegas V., Ramírez E., Rendón Y., Suárez A., Morales L., Useche E., Salazar S., Zambrano A., Ramírez Á.., Valderrama E., Briceño Z., Chiurillo M. Á., TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela. Investigacion Clinica 2009 50 2 153 161 2-s2.0-70349579122
135. Zhou Y., Li N., Zhuang W., Wu X., P53 codon 72 polymorphism and gastric cancer risk in a Chinese Han population. Genetic Testing and Molecular Biomarkers 2010 14 6 829 833 2-s2.0-78650385081 10.1089/gtmb.2010.0115
136. Pérez-Pérez G. I., Bosques-Padilla F. J., Crosatti M. L., Tijerina-Menchaca R., Garza-González E., Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scandinavian Journal of Gastroenterology 2005 40 1 56 60 2-s2.0-12444315955 10.1080/00365520410009456
137. Zhang Z. W., Newcomb P., Hollowood A., Moganaden, Gupta J., Feakins R., Storey A., Farthing M. J. G., Alderson D., Holly J., A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Digestive Diseases and Sciences 2004 49 2 254 259 2-s2.0-12144287947 10.1023/B:DDAS.0000017447.02220.f5 (Pubitemid 38392226)
138. Khayat A. S., Lobo Gatti L., Moura Lima E., De Assumpção P. P., Nascimento Motta F. J., Harada M. L., Casartelli C., Marques Payão S. L., Cardoso Smith M. A., Burbano R. R., Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. Clinical and Experimental Medicine 2005 5 4 161 168 2-s2.0-29144478593 10.1007/s10238-005-0081-4 (Pubitemid 41813759)
139. Xi Y. G., Ding K. Y., Su X. L., Chen D. F., You W. C., Shen Y., Ke Y., p53 polymorphism and p21 WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 2004 25 11 2201 2206 2-s2.0-8844285188 10.1093/carcin/bgh229 (Pubitemid 39534858)
140. Crew K. D., Neugut A. I., Epidemiology of gastric cancer. World Journal of Gastroenterology 2006 12 3 354 362 2-s2.0-33644681327 (Pubitemid 43329250)
141. Feng Z., Zhang C., Wu R., Hu W., Tumor suppressor p53 meets microRNAs. Journal of Molecular Cell Biology 2011 3 1 44 50 2-s2.0-79951486506 10.1093/jmcb/mjq040